CN117547025A - Composition for controlling weight as well as preparation method and application thereof - Google Patents
Composition for controlling weight as well as preparation method and application thereof Download PDFInfo
- Publication number
- CN117547025A CN117547025A CN202410046372.1A CN202410046372A CN117547025A CN 117547025 A CN117547025 A CN 117547025A CN 202410046372 A CN202410046372 A CN 202410046372A CN 117547025 A CN117547025 A CN 117547025A
- Authority
- CN
- China
- Prior art keywords
- weight
- powder
- parts
- lactobacillus
- weight control
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 66
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 56
- 241001070941 Castanea Species 0.000 claims abstract description 21
- 235000014036 Castanea Nutrition 0.000 claims abstract description 21
- 240000000249 Morus alba Species 0.000 claims abstract description 20
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 20
- 241000186660 Lactobacillus Species 0.000 claims abstract description 18
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 18
- 241001474374 Blennius Species 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 13
- 230000037221 weight management Effects 0.000 claims abstract description 7
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims abstract description 4
- 238000007873 sieving Methods 0.000 claims abstract description 4
- 238000004260 weight control Methods 0.000 claims description 34
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 14
- 241000894006 Bacteria Species 0.000 claims description 7
- 235000014655 lactic acid Nutrition 0.000 claims description 7
- 239000004310 lactic acid Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 210000000582 semen Anatomy 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 abstract description 7
- 238000010521 absorption reaction Methods 0.000 abstract description 7
- 235000020824 obesity Nutrition 0.000 abstract description 7
- 230000001603 reducing effect Effects 0.000 abstract description 7
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 235000013305 food Nutrition 0.000 abstract description 4
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 230000001079 digestive effect Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- 230000000694 effects Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 238000000354 decomposition reaction Methods 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 9
- 235000014633 carbohydrates Nutrition 0.000 description 9
- 235000012054 meals Nutrition 0.000 description 9
- 230000004584 weight gain Effects 0.000 description 8
- 235000019786 weight gain Nutrition 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 6
- 238000013116 obese mouse model Methods 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000029087 digestion Effects 0.000 description 5
- 150000002016 disaccharides Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 238000009825 accumulation Methods 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000013589 supplement Substances 0.000 description 4
- 102000004139 alpha-Amylases Human genes 0.000 description 3
- 108090000637 alpha-Amylases Proteins 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 229940024171 alpha-amylase Drugs 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 150000002772 monosaccharides Chemical class 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710184309 Probable sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102400000472 Sucrase Human genes 0.000 description 2
- 101710112652 Sucrose-6-phosphate hydrolase Proteins 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 102000016679 alpha-Glucosidases Human genes 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 125000000600 disaccharide group Chemical group 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 235000016425 Arthrospira platensis Nutrition 0.000 description 1
- 240000002900 Arthrospira platensis Species 0.000 description 1
- 241000512259 Ascophyllum nodosum Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 206010004716 Binge eating Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010059881 Lactase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 241000264279 Sargassum fusiforme Species 0.000 description 1
- 241001260874 Sargassum horneri Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241001261506 Undaria pinnatifida Species 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 208000014679 binge eating disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003979 granulating agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229940116108 lactase Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 229940082787 spirulina Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000021076 total caloric intake Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940054810 white kidney bean extract Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/60—Edible seaweed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L25/00—Food consisting mainly of nutmeat or seeds; Preparation or treatment thereof
- A23L25/30—Mashed or comminuted products, e.g. pulp, pastes, meal, powders; Products made therefrom, e.g. blocks, flakes, snacks; Liquid or semi-liquid products
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Botany (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
The invention discloses a composition for controlling weight, a preparation method and application thereof, and belongs to the technical field of weight management, wherein the composition comprises the following raw materials in parts by weight: 5-25 parts of seaweed powder, 10-60 parts of chestnut powder, 10-30 parts of mulberry leaf extract and 0.04-0.1 part of lactobacillus powder; the lactobacillus in the lactobacillus powder is Lactobacillus paracasei YJS05199. The preparation method comprises mixing seaweed powder, chestnut powder, mulberry leaf extract and lactobacillus powder according to the formula amount, and sieving. The composition of the present invention blocks caloric absorption against the food digestive path, and reduces excessive caloric conversion to fat, thereby reducing the formation of obesity.
Description
Technical Field
The invention relates to the technical field of weight management, in particular to a composition for controlling weight, a preparation method and application thereof.
Background
Maintaining a desired weight is challenging for many people. Furthermore, as people age, maintaining a desired weight generally becomes more difficult. Excessive or undesired body weight may be caused by an imbalance in caloric (energy) intake and energy expenditure. Such imbalance may be related to a variety of factors, including: binge eating, non-active or sedentary lifestyle, familial genetics and various medical conditions, etc. In order to prevent or prevent obesity or overweight, lifestyle changes may be one of the main solutions, however, in general lifestyle changes may be difficult to implement, resulting in poor results.
Dietary planning, reducing total caloric intake from the diet can help maintain a desired weight, including reducing dietary intake, or ingesting medications or supplements such as caloric blockers, meal replacers, appetite reducers, and the like. However, the effectiveness of currently available drugs or supplements in promoting weight control or weight loss is unpredictable. The efficacy of these drugs or supplements is questionable if they are not used in conjunction with caloric restricted diets and exercise regimens.
Thus, the lack of effective drugs or supplements to promote weight control or weight loss is currently a challenge for weight management.
Disclosure of Invention
The invention aims to provide a composition for controlling weight, a preparation method and application thereof, wherein the composition blocks heat absorption through a whole link aiming at a food digestion path, reduces excessive heat to be converted into fat, and thus reduces the formation of obesity.
In order to achieve the above purpose, the present invention adopts the following technical scheme:
in a first aspect, the present invention provides a weight control composition comprising seaweed meal, chestnut meal, mulberry leaf extract and lactic acid bacteria meal.
The weight control composition of the present invention can achieve full-link heat absorption blocking by blocking carbohydrate decomposition into disaccharides, disaccharide decomposition into monosaccharides, lipase decomposition, etc., and reduce the conversion of excess heat into fat, thereby reducing the formation of obesity. Specifically, the seaweed meal can inhibit the digestion and decomposition of fat by inhibiting the activity of alpha-amylase in the oral cavity to block the decomposition of carbohydrate into disaccharides (maltose, sucrose and lactose) and inhibiting the activity of intestinal lipase; chestnut powder can block the decomposition of carbohydrate into disaccharide by inhibiting the activity of alpha-amylase in the oral cavity and stomach, inhibit the activity of maltase and sucrase in the small intestine and block the decomposition of disaccharide into monosaccharide; the mulberry leaf extract can act on a plurality of parts to block heat absorption, for example, can act on the oral cavity and the stomach to inhibit the activity of alpha-amylase and block the decomposition of carbohydrate into disaccharide, can act on the small intestine to inhibit the activities of alpha-glucosidase, maltase, sucrase and lactase and block the decomposition of disaccharide into monosaccharide, can act on blood vessels to block the entry of glucose into blood vessels, and can relieve insulin resistance and reduce blood sugar; the Lactobacillus paracasei YJS05199 can act on small intestine, and is combined with a-glucosidase preferentially, so that starch food is inhibited from being combined with the enzymes to produce decomposition and digestion, and can act on blood vessels to increase glucose metabolism level obviously.
In some specific embodiments, the weight control composition comprises the following raw materials in parts by weight: 5-25 parts of seaweed powder, 10-60 parts of chestnut powder, 10-30 parts of mulberry leaf extract and 0.04-0.1 part of lactobacillus powder.
Preferably, the mass ratio of the chestnut powder to the mulberry leaf extract to the lactobacillus powder is 20-50:12-25:0.04-0.01.
In some specific embodiments, the weight control composition comprises the following raw materials in parts by weight: 10-25 parts of seaweed powder, 20-50 parts of chestnut powder, 12-25 parts of mulberry leaf extract and 0.04-0.1 part of lactobacillus powder.
Preferably, the mass ratio of the chestnut powder to the mulberry leaf extract to the lactobacillus powder is 30:20:0.05.
in some specific embodiments, the weight control composition comprises the following raw materials in parts by weight: 20 parts of seaweed powder, 30 parts of chestnut powder, 20 parts of mulberry leaf extract and 0.05 part of lactobacillus powder.
In a second aspect, the present invention provides a method for preparing the above composition for controlling body weight, comprising the steps of mixing seaweed meal, chestnut meal, mulberry leaf extract and lactic acid bacteria meal, and sieving.
In a third aspect, the present invention provides the use of a weight control composition as described above for the preparation of a caloric blocker.
In a fourth aspect, the present invention provides a caloric blocker comprising the above-described weight control composition.
In a fifth aspect, the present invention provides the use of a weight control composition as described above for the preparation of a weight control product.
In a sixth aspect, the invention provides a weight management product comprising a weight management composition as described above.
The product is granular, powdery or blocky.
The beneficial effects of the invention are as follows:
(1) The weight control composition disclosed by the invention is prepared by carefully selecting seaweed powder, chestnut powder, mulberry leaf extract and lactobacillus powder (Lactobacillus paracasei YJS 05199) for compounding, and aims at a food digestion path, so that full-link heat absorption is blocked, excessive heat is reduced to be converted into fat, and the formation of obesity is effectively reduced.
(2) Experiments show that when the weight control composition comprises 20-50% of chestnut powder, 20% of mulberry leaf extract and 20% of lactobacillus powder by mass: 12-25: when the weight is 0.04-0.1, the effects of reducing fat and weight are better.
Detailed Description
The following examples are presented only to aid in understanding the method of the present invention and its core ideas. It should be noted that it will be apparent to those skilled in the art that various modifications and adaptations of the invention can be made without departing from the principles of the invention and these modifications and adaptations are intended to be within the scope of the invention as defined in the following claims. The following description of the disclosed embodiments is provided to enable any person skilled in the art to make or use the invention. Various modifications to these embodiments will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other embodiments without departing from the spirit or scope of the invention. Thus, the present invention is not intended to be limited to the embodiments shown herein but is to be accorded the widest scope consistent with the principles and novel features disclosed herein. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The invention does not limit the sources of the adopted raw materials, and if no special description exists, the adopted raw materials are all common commercial products in the technical field.
The seaweed powder is obtained by cleaning seaweed such as spirulina, undaria pinnatifida, kelp, sargassum horneri and sargassum fusiforme to remove sediment impurities, drying and crushing. For example, available from Tianjin coastal strapdown proprietary chemical industry Co., ltd., product number: 202041. the seaweed meal is used in an amount of 5 to 25 parts by weight, preferably 5 parts by weight, 10 parts by weight, 20 parts by weight, 25 parts by weight, and more preferably 20 parts by weight.
The chestnut powder is chestnut raw powder; such as available from Shaanxi Humicon development Co., ltd., product number: HK20230517. The amount of the chestnut powder is 10-60 parts by weight, preferably 10 parts by weight, 20 parts by weight, 30 parts by weight, 50 parts by weight and 60 parts by weight; further preferably 30 parts by weight.
The mulberry leaf extract of the present invention contains 1-deoxynojirimycin in an amount of not less than 1wt%, for example, commercially available from the company of biotechnology Co., ltd. The mulberry leaf extract is used in an amount of 10-30 parts by weight, preferably 10 parts by weight, 12 parts by weight, 20 parts by weight, 25 parts by weight, 30 parts by weight; further preferably 20 parts by weight.
The lactic acid bacteria powder of the present invention contains 55wt% maltodextrin and 45wt% of Lactobacillus paracasei YJS05199, wherein the Lactobacillus paracasei YJS05199 is inactivated, and is available from, for example, the biological technology Co., ltd. In the middle-aged Cryptographic (Shanghai), commercial product number: yl.kh.12.00181. The amount of the lactic acid bacteria powder is 0.04 to 0.1 part by weight, preferably 0.04 part by weight, 0.05 part by weight, 0.06 part by weight, 0.08 part by weight, 0.1 part by weight, and more preferably 0.05 part by weight.
It was unexpectedly found in the test that when the mass ratio of chestnut powder, mulberry leaf extract and lactic acid bacteria powder is 20-50:12-25: at 0.04-0.1, the weight-controlling composition of the present invention exhibits a better lipid-lowering effect.
The "weight control composition", "caloric blocker" and "weight control product" described herein are generally compositions comprising a number of weight control compositions (abbreviated as active ingredients) and pharmaceutically acceptable excipients, and in particular embodiments, the active ingredients described herein are provided in the compositions in an effective amount (e.g., a therapeutically effective amount).
The "pharmaceutically acceptable auxiliary materials" in the present invention include inert diluents, dispersants and/or granulating agents, surfactants and/or emulsifying agents, disintegrants, binders, preservatives, buffers, lubricants and/or oils. Excipients, colorants, coatings, sweeteners, and flavoring agents may also be present in the composition.
The compositions of the present invention may be prepared by any method known in the art of pharmacy. Generally, these methods of preparation involve associating the active ingredient with a carrier or excipient and/or one or more other auxiliary ingredients, and then shaping and/or packaging the product into the desired single or multi-dose unit if needed and/or desired.
The composition of the present invention can be prepared according to a known method, for example, the method set forth in the general rules for the preparation of japanese pharmacopoeia (Japanese Pharmacopoeia) 16 th edition, united states pharmacopoeia (United States Pharmacopoeia) and european pharmacopoeia (European Pharmacopoeia) 9 th edition. Depending on the dosage form, the compositions of the present invention may be suitably administered to patients. For example, the compositions of the present invention may be in the form of granules, powders or cubes.
The active ingredients, adjuvants in the compositions herein will vary depending on the nature, size and/or condition of the subject being treated and further depending on the route of administration of the composition. The composition may comprise between 0.1% and 100% (w/w) active ingredient.
By "controlling body weight" as used herein is meant treating or alleviating obesity by providing a higher amount of calories consumed than ingested. "treating" in the present invention, unless indicated otherwise, means reversing, alleviating, inhibiting the progression of, or preventing a disorder or condition for which the term applies or one or more symptoms of such disorder or condition.
The heat blocker can also be called as a carbohydrate blocker or a carbohydrate blocker, and can inhibit decomposition and absorption of carbohydrates by a human body, so that digestion and absorption of the carbohydrates by the human body are reduced, the carbohydrates are prevented from being converted into fat, and the purpose of controlling the weight is achieved.
The weight control composition, the heat blocker and the weight control product can be used as raw materials in health care products and medicines. In the case where the "weight control composition", "caloric blocker" and "weight control product" of the present invention are used as raw materials, the "weight control composition", "caloric blocker" and "weight control product" are preferably contained in a proportion of 10% to 90% by weight.
The following examples and comparative examples of the present invention will be described in more detail with respect to the weight control composition of the present invention, but the present invention is not limited thereto.
Purchase information of the raw materials is shown in table 1 below.
TABLE 1
Examples 1 to 5 and comparative examples 1 to 5
Weight control compositions of the different examples and comparative examples were prepared according to Table 2 and the following preparation methods
The preparation method comprises the following steps: mixing seaweed powder, semen Castaneae powder, folium Mori extract and lactobacillus powder, and sieving with 80 mesh sieve.
TABLE 2 formulation of weight controlling compositions prepared in examples 1-5 and comparative examples 1-5 (unit: parts by weight)
The raw materials in the table are white kidney bean extract, which is purchased from Sieboldite Biotechnology Co., ltd. Alpha. -AIP is 20000u/g, and the "-" in the table indicates no addition.
Weight loss function test
Healthy male C57BL/6 mice of 5 weeks of age were selected, and after 3 days of adaptive feeding, they were randomly divided into 12 groups of a normal group, a model group and a composition group (examples 1 to 5 and comparative examples 1 to 5) according to body weight, 8 groups each. The normal group is continuously fed with basic feed (purchased from the medical animal experiment center in Guangdong province), the model group and the composition group are fed with high-fat nutritional feed (prepared from 80% of basic feed, 10% of lard and 10% of yolk powder, purchased from the medical animal experiment center in Guangdong province), and the feeding amount is 2.5g/25g of mouse weight per day.
The composition group was filled with the same amount of physiological saline as that of the normal group and the model group, and was continuously filled with the same amount of physiological saline for 4 weeks, per day, per weight of the mice prepared in the corresponding examples and comparative examples. All groups of mice were normally drinking and exercising during the trial, and the mice were weighed at week 1 and week 4 after the gavage composition, respectively. At the end of the experiment, body fat (testis and perirenal fat pad) was dissected and weighed.
SPSS16.0 software is adopted to carry out single factor analysis of variance, and the processed data are expressed as mean value plus or minus standard deviationS) represents.
The results are shown in tables 3 to 4.
TABLE 3 weight of rats of different groups±s)
Note that: p < 0.05, P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.05, and the # P is less than 0.01; compared with the group of example 5, ΔP is less than 0.05, ΔΔP is less than 0.01.
As can be seen from table 3, there was no significant difference between the initial weights of the mice in each group.
After one week of feeding, the body weight of mice in the model group had a very significant difference (P < 0.01) compared to the normal group, indicating that high diet can induce mice to develop obesity.
The weight loss of the mice in the groups of examples 1-5 all had very significant differences (P < 0.01) compared to the model group, while the weight loss of the mice in the groups of comparative examples 1-5 all had no significant differences (P > 0.05), indicating that the compositions of the present invention significantly alleviated weight gain in obese mice induced by a high fat diet, whereas the compositions provided by the comparative examples did not alleviate weight gain in obese mice induced by a high fat diet.
The weight gain of the mice in the comparative examples 1-5 was significantly different (P < 0.05) compared to the group of example 5, indicating that the compositions of the present invention had better effect on alleviating weight gain in obese mice induced by a high fat diet than the compositions provided in comparative examples 1-5.
After 4 weeks of continuous feeding, the weight loss of mice in the groups of examples 1-5 all had very significant differences (P < 0.01) compared to the model group, while the weight loss of mice in the groups of comparative examples 1-5 all had no significant differences (P > 0.05), indicating that the compositions of the present invention can significantly alleviate weight gain in obese mice induced by a high-fat diet, whereas the compositions provided by the comparative examples did not have the effect of alleviating weight gain in obese mice induced by a high-fat diet.
The weight gain of the mice in the comparative examples 1-5 was very significantly different (P < 0.01) compared to the group of example 5, indicating that the compositions of the present invention had a better effect of alleviating weight gain in obese mice induced by a high fat diet than the compositions provided in comparative examples 1-5.
Table 4 shows the total weight of fat in rats of different groups around±s)
Note that: p < 0.05, P < 0.01 compared to normal group; compared with the model group, the # P is less than 0.05, and the # P is less than 0.01; compared with the group of example 5, ΔP is less than 0.05, ΔΔP is less than 0.01.
As can be seen from Table 4, after 4 weeks of gastric lavage, the total fat in the mice of the model group had a very significant difference (P < 0.01) compared to the normal group, indicating that there was significant fat accumulation in the mice of the model group.
Compared with the model group, the total amount of fat in mice in the groups of examples 1-5 has extremely significant difference (P < 0.01), and the total amount of fat in mice in the groups of comparative examples 1-5 has no significant difference (P > 0.05), which shows that the composition of the invention can significantly reduce fat accumulation in mice, and the composition provided by the comparative example has no effect of reducing fat accumulation in mice.
The total fat levels of the mice in the comparative examples 1-5 were significantly different (P < 0.01) compared to the group of example 5, indicating that the compositions of the present invention had better fat accumulation reducing effects than the compositions provided in comparative examples 1-5.
The invention has been further described above in connection with specific embodiments, which are exemplary only and do not limit the scope of the invention in any way. It will be understood by those skilled in the art that various changes and substitutions of details and forms of the technical solution of the present invention may be made without departing from the spirit and scope of the present invention, but these changes and substitutions fall within the scope of the present invention.
Claims (10)
1. The weight control composition is characterized by comprising the following raw materials in parts by weight: 5-25 parts of seaweed powder, 10-60 parts of chestnut powder, 10-30 parts of mulberry leaf extract and 0.04-0.1 part of lactobacillus powder;
the lactobacillus in the lactobacillus powder is Lactobacillus paracasei YJS05199.
2. The weight control composition according to claim 1, wherein the mass ratio of chestnut powder, mulberry leaf extract and lactic acid bacteria powder is 20-50:12-25:0.04-0.1.
3. The weight control composition according to claim 2, characterized by comprising the following raw materials in parts by weight: 10-25 parts of seaweed powder, 20-50 parts of chestnut powder, 12-25 parts of mulberry leaf extract and 0.04-0.1 part of lactobacillus powder.
4. A weight control composition according to claim 3, wherein the mass ratio of chestnut powder, mulberry leaf extract and lactic acid bacteria powder is 30:20:0.05.
5. the weight control composition according to claim 4, comprising the following raw materials in parts by weight: 20 parts of seaweed powder, 30 parts of chestnut powder, 20 parts of mulberry leaf extract and 0.05 part of lactobacillus powder.
6. A method for preparing a weight control composition according to any one of claims 1 to 5, comprising the steps of: mixing seaweed powder, semen Castaneae powder, folium Mori extract and lactobacillus powder, and sieving.
7. Use of a weight control composition according to any one of claims 1-5 for the preparation of a caloric blocker.
8. A caloric blocker comprising the weight control composition of any one of claims 1-5.
9. Use of a weight control composition according to any one of claims 1-5 for the preparation of a weight control product.
10. A weight management product comprising a weight management composition according to any one of claims 1 to 5.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410046372.1A CN117547025B (en) | 2024-01-12 | 2024-01-12 | Composition for controlling weight as well as preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410046372.1A CN117547025B (en) | 2024-01-12 | 2024-01-12 | Composition for controlling weight as well as preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN117547025A true CN117547025A (en) | 2024-02-13 |
CN117547025B CN117547025B (en) | 2024-04-26 |
Family
ID=89811516
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410046372.1A Active CN117547025B (en) | 2024-01-12 | 2024-01-12 | Composition for controlling weight as well as preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117547025B (en) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05284937A (en) * | 1992-04-10 | 1993-11-02 | T Ee C Gijutsu Kagaku Kenkyusho:Kk | Digestive enzyme activity-inhibiting substance extracted from sea alga and dietary food containing the same |
KR20030021215A (en) * | 2003-02-12 | 2003-03-12 | 주식회사 아미노젠 | Anti-obesity constituents contained natural dietary fiber and functional ingredient, and dietary supplementation food made by using it as the effective component. |
US20070202205A1 (en) * | 2004-09-13 | 2007-08-30 | TakahiroTSUJITA | Carbohydrase Inhibitors Derived From Chestnut And Use Thereof |
JP2008120772A (en) * | 2006-11-08 | 2008-05-29 | Bhn Kk | Obesity inhibitor and edible composition |
KR20150080983A (en) * | 2014-01-02 | 2015-07-13 | 고려대학교 산학협력단 | Fermented Castanea crenata inner shell extracts for anti-obesity and manufacturing method thereof |
CN104814192A (en) * | 2015-05-14 | 2015-08-05 | 安徽富从春商贸有限公司 | White mulberry root bark-containing healthcare tea beverage |
CN113712206A (en) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method |
CN116235955A (en) * | 2023-05-12 | 2023-06-09 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
CN116836893A (en) * | 2023-08-31 | 2023-10-03 | 北京新浠芮生物技术有限公司 | Lactobacillus paracasei, and metaplastic product and application thereof |
CN117044945A (en) * | 2023-10-09 | 2023-11-14 | 北京衡美金叶营养健康科技有限公司 | Food composition with function of controlling blood sugar rise, and preparation method and application thereof |
CN117137136A (en) * | 2023-08-14 | 2023-12-01 | 杭州千岛湖康诺邦健康产品有限公司 | Composition with fat reducing function and preparation method and application thereof |
-
2024
- 2024-01-12 CN CN202410046372.1A patent/CN117547025B/en active Active
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05284937A (en) * | 1992-04-10 | 1993-11-02 | T Ee C Gijutsu Kagaku Kenkyusho:Kk | Digestive enzyme activity-inhibiting substance extracted from sea alga and dietary food containing the same |
KR20030021215A (en) * | 2003-02-12 | 2003-03-12 | 주식회사 아미노젠 | Anti-obesity constituents contained natural dietary fiber and functional ingredient, and dietary supplementation food made by using it as the effective component. |
US20070202205A1 (en) * | 2004-09-13 | 2007-08-30 | TakahiroTSUJITA | Carbohydrase Inhibitors Derived From Chestnut And Use Thereof |
JP2008120772A (en) * | 2006-11-08 | 2008-05-29 | Bhn Kk | Obesity inhibitor and edible composition |
KR20150080983A (en) * | 2014-01-02 | 2015-07-13 | 고려대학교 산학협력단 | Fermented Castanea crenata inner shell extracts for anti-obesity and manufacturing method thereof |
CN104814192A (en) * | 2015-05-14 | 2015-08-05 | 安徽富从春商贸有限公司 | White mulberry root bark-containing healthcare tea beverage |
CN113712206A (en) * | 2021-09-16 | 2021-11-30 | 湖南希尔天然药业有限公司 | A composition containing folium Mori DNJ and folium Mori peptide and its preparation method |
CN116235955A (en) * | 2023-05-12 | 2023-06-09 | 北京新浠芮生物技术有限公司 | Composition with functions of balancing immunity and protecting liver |
CN117137136A (en) * | 2023-08-14 | 2023-12-01 | 杭州千岛湖康诺邦健康产品有限公司 | Composition with fat reducing function and preparation method and application thereof |
CN116836893A (en) * | 2023-08-31 | 2023-10-03 | 北京新浠芮生物技术有限公司 | Lactobacillus paracasei, and metaplastic product and application thereof |
CN117044945A (en) * | 2023-10-09 | 2023-11-14 | 北京衡美金叶营养健康科技有限公司 | Food composition with function of controlling blood sugar rise, and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117547025B (en) | 2024-04-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103238897B (en) | Composite plant solid drink suitable for diabetic patients | |
US20190328817A1 (en) | Traditional chinese medicine healthcare preparation for fat elimination and weight reduction | |
CA2559755C (en) | Dietary supplement and method for treating digestive system-related disorders | |
CN103431392B (en) | Composite marine food for special dietary uses for diabetics | |
ZA200607919B (en) | Dietary supplement and method for treating digestive system-related disorders | |
JP2005034135A (en) | Functionally reinforcing composition for common food, health functional food or health supplemental food, and method for the same | |
JP2007181447A (en) | Buckwheat noodle enriched in ingredient and method for producing the same | |
CN109393493A (en) | A kind of predigestion type pancebrin of the calcium containing HMB and preparation method thereof | |
CN112137115A (en) | Ketogenic nutrition powder with immunity enhancing effect and preparation method thereof | |
JP5130593B2 (en) | Explosive fermented dietary fiber-containing composition | |
CN102150838A (en) | Weight losing composition, preparation containing same and preparation method thereof | |
CN117547025B (en) | Composition for controlling weight as well as preparation method and application thereof | |
US5994326A (en) | Anti-atopic dermatitis composition | |
KR20200016608A (en) | The health food composition for regulating weight | |
BE1020284A3 (en) | COMPOSITION TO OBTAIN POSITIVE HEALTH EFFECTS. | |
CN107467193A (en) | Full nutrition special medicine purposes formula food of a kind of pulvis based on goat milk and preparation method thereof | |
KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
CN109043554A (en) | A kind of Special food of high dietary-fiber and preparation method thereof | |
CN111000243B (en) | Application of composition of oligosaccharide and lactein in food and health products | |
JP2006020606A (en) | Composition for health food for obesity prevention and amelioration | |
CN101129406A (en) | Formula of compound colla carapaeis corii asini series products and method for producing the same | |
Sacks et al. | Case report: the effect of tetrahydrocannabinol on food intake during chemotherapy. | |
CN108669530A (en) | A kind of Hericium erinaceus composition, tablet and preparation method conducive to stomach health | |
CN103750308A (en) | Composition with effect of improving gastrointestinal functions | |
CN115006432B (en) | Probiotic composition for resisting helicobacter pylori |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |